Fundraising Fox
Interpace
OTC: IDXGPittsburgh, US · 2 known investors
Find your way into Interpace
Sign up to see every warm intro you have to Interpace
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Interpace team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Interpace Biosciences provides molecular diagnostic tests for the early diagnosis and treatment of cancer, with a focus on risk-stratifying indeterminate thyroid nodules through genetic and mutational analysis. The company serves specialty physicians and medical centers in the U.S. and internationally.
Founders & leadership
CM
TW
Thomas W. BurnellExecutiveOperating Team Member at 1315 Capital
JE
James EarlyCFO
JE
Jack E StoverPresident and CEO
Board
SJ
Stephen J. SullivanBoard director
VA
Vijay AggarwalBoard director
JK
Joseph KeeganBoard director
FR
Fortunato Ron RoccaBoard director
Investors · 2
1315 Capitallisted by 1315 CapitalPhiladelphia · $5M – $40M
How we know: 1315 Capital's portfolio page · the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$113.1M disclosed across 5 rounds · 2017–2024
▶$47MraisedOct 2024 · 2 investors · Other Health CareRule 506(b)
▶$47MraisedOct 2024 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stephen J. SullivanDirector
- Vijay AggarwalDirector
- Joseph KeeganDirector
- Fortunato Ron RoccaDirector
- Christopher McCarthyExecutive Officer
- Thomas W. BurnellExecutive Officer, Director
- Offering amount
- $47M
- Amount sold
- $47M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$47MraisedJan 2020 · 2 investors · Other Health CareRule 506(b)
▶$47MraisedJan 2020 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Felice Schnoll-SussmanDirector
- Gregory RichardExecutive Officer
- Eric LevDirector
- Laurence R. McCarthyDirector
- Robert GormanDirector
- Thomas FreeburgExecutive Officer
- Fortunato Ron RoccaDirector
- Jack E. StoverExecutive Officer, Director
- James EarlyExecutive Officer
- Joseph KeeganDirector
- Stephen J. SullivanDirector
- Edward ChanDirector
- Offering amount
- $47M
- Amount sold
- $47M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14MraisedJul 2019 · 1 investors · Other Health CareRule 506(b)
▶$14MraisedJul 2019 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jack E. StoverExecutive Officer, Director
- James EarlyExecutive Officer
- Joseph KeeganDirector
- Stephen J. SullivanDirector
- Thomas FreeburgExecutive Officer
- Felice Schnoll-SussmanDirector
- Gregory RichardExecutive Officer
- Eric LevDirector
- Offering amount
- $27M
- Amount sold
- $14M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedOct 2017 · 4 investors · Other Health CareRule 506(b)
▶$5MraisedOct 2017 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Gregory RichardExecutive Officer
- Felice Schnoll-SussmanDirector
- James EarlyExecutive Officer
- Jack E. StoverExecutive Officer, Director
- Stephen J. SullivanDirector
- Joseph KeeganDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Sales commissions
- $225K
- Placement agents
- Maxim Group LLC
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$111.2KraisedJan 2017 · 6 investors · Other Health CareRule 506(b)
▶$111.2KraisedJan 2017 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- James EarlyExecutive Officer
- Jack E StoverExecutive Officer, Director
- Stephen J SullivanDirector
- Joseph KeeganDirector
- Offering amount
- $4.1M
- Amount sold
- $111.2K
- Sales commissions
- $329.7K
- Proceeds to insiders
- $111K
- Placement agents
- Maxim Group LLC
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Interpace do?
- Interpace Biosciences provides molecular diagnostic tests for the early diagnosis and treatment of cancer, with a focus on risk-stratifying indeterminate thyroid nodules through genetic and mutational analysis. The company serves specialty physicians and medical centers in the U.S. and internationally.
- Who are Interpace's investors?
- Interpace's investors include 1315 Capital, Ampersand.
- How much funding has Interpace raised?
- Interpace has disclosed $113.1M raised across 5 rounds.
- Where is Interpace headquartered?
- Interpace is headquartered in Pittsburgh, US.